Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
| Autor: | Funderburg NT; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, OH 43210, USA. Electronic address: nicholas.funderburg@osumc.edu., McComsey GA; Case Western Reserve University, Cleveland, OH 44106, USA; Rainbow Babies and Children's Hospital, University Hospitals Case Medical Center, Cleveland, OH, 44106, USA., Kulkarni M; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, OH 43210, USA., Bannerman T; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, OH 43210, USA., Mantini J; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, OH 43210, USA., Thornton B; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, OH 43210, USA., Liu HC; Gilead Sciences Inc., Foster City, CA 94404, USA., Zhang Y; Gilead Sciences Inc., Foster City, CA 94404, USA., Song Q; Gilead Sciences Inc., Foster City, CA 94404, USA., Fang L; Gilead Sciences Inc., Foster City, CA 94404, USA., Dinoso J; Gilead Sciences Inc., Foster City, CA 94404, USA., Cheng A; Gilead Sciences Inc., Foster City, CA 94404, USA., McCallister S; Gilead Sciences Inc., Foster City, CA 94404, USA., Fordyce MW; Gilead Sciences Inc., Foster City, CA 94404, USA., Das M; Gilead Sciences Inc., Foster City, CA 94404, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | EBioMedicine [EBioMedicine] 2016 Nov; Vol. 13, pp. 321-327. Date of Electronic Publication: 2016 Oct 11. |
| DOI: | 10.1016/j.ebiom.2016.10.009 |
| Abstrakt: | Background: Initiation of antiretroviral therapy (ART) and subsequent virologic suppression reduces immune activation and systemic inflammation. Methods: We examined longitudinal changes in biomarkers of monocyte activation (sCD14, sCD163), and systemic (IL-6, hsCRP, sTNFR-I and D-dimer) and vascular (Lp-PLA Results: For 194 participants (TAF, 98; TDF, 96), baseline levels of biomarkers did not differ by treatment arm; there were no differences in biomarker values between groups at weeks 12, 24, or 48 (p>0.05), except IL-6 at week 12 (p=0.012). Among all participants (combining groups), there were statistically significant declines from baseline observed for D-dimer, sCD163, and sTNFR-1 by week 12 and IL-6 by week 24. The proportion of participants with Lp-LA Conclusions: We observed equivalent declines in biomarkers of monocyte activation and systemic inflammation in treatment-naïve adults treated with TAF or TDF for 48weeks, suggesting that TAF and TDF have equivalent impact on immune activation and inflammation. (Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|